Concurrent Doxorubicin Plus Docetaxel Is Not More Effective Than Concurrent Doxorubicin Plus Cyclophosphamide in Operable Breast Cancer With 0 to 3 Positive Axillary Nodes: North American Breast Cancer Intergroup Trial E 2197

PURPOSE: The combination of doxorubicin and cyclophosphamide (AC) is a standard adjuvant regimen. Doxorubicin and docetaxel (AT) is one of the most active cytotoxic regimens for metastatic breast cancer. The purpose of this trial was to determine whether adjuvant AT improved disease-free survival co...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Goldstein, Lori J., O'Neill, Anne, Sparano, Joseph A., Perez, Edith A., Shulman, Lawrence N., Martino, Silvana, Davidson, Nancy E.
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Clinical Oncology 2008
Ämnen:
Breast Cancer
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2654376/
https://ncbi.nlm.nih.gov/pubmed/18678836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.16.7841
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk